Search
Protein S human
go.drugbank.com/drugs/DB13149ApprovedInvestigationalProtein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties . It serves as a negative feedback mechanism in the coagulation cascade.
Diflunisal
go.drugbank.com/drugs/DB00861ApprovedDiflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though it...
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedIt was discovered by phage display technology [A32017]. … The amino acid sequence of two compounds differ by seven amino acids [L1458].
Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigationalOften, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12.
Pancrelipase protease
go.drugbank.com/drugs/DB11066ApprovedInvestigational[L2509] The pancrelipase protease is a mix of enzymes, formed by trypsin and chymotrypsin, that proteolytically cleave peptide bonds and are involved in food digestion. … [A32742, L2543] The pancrelipase mixture, including pancrelipase protease, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Eperisone
go.drugbank.com/drugs/DB08992InvestigationalIt is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.
Pipradrol
go.drugbank.com/drugs/DB11584ApprovedWithdrawnPipradrol (Meratran) [L2523] was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international
Grapiprant
go.drugbank.com/drugs/DB12836InvestigationalVet approved[L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836] … [A39816] This class of drugs was defined in 2013 by the World Health Organization.
Valsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigationalARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … [A174154] By comparison, the angiotensin-converting enzyme inhibitor (ACEI) class of medications (which includes drugs such as [ramipril], [lisinopril], and [perindopril]) inhibit the conversion of
CCX915
go.drugbank.com/drugs/DB05159ExperimentalCCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.